The impacts of genetic polymorphisms in genes of base excision repair pathway on the efficacy and acute toxicities of (chemo)radiotherapy in patients with nasopharyngeal carcinoma
Metrics: PDF 946 views | HTML 1313 views | ?
Jing Wang1,2,*, Chengxian Guo3,*, Xiaochang Gong1, Fan Ao1, Yuling Huang1, Lihua Huang4, Yiqiang Tang1, Chunling Jiang1, Xiaoxue Xie5, Qing Dong1,6, Min Huang1 and Jingao Li1
1Department of Radiation Oncology, Jiangxi Cancer Hospital, Nanchang 330029, China
2Department of Intensive Care Unit, Jiangxi Cancer Hospital, Nanchang 330029, China
3Center of Clinical Pharmacology, Third Xiangya Hospital, Central South University, Changsha 410013, China
4Center for Medical Experiments, Third Xiangya Hospital, Central South University, Changsha 410013, China
5Department of Radiation and Oncology, Hunan Provincial Tumor Hospital and Affiliated Tumor Hospital of Xiangya Medical School, Central South University, Changsha 410013, China
6Department of Graduate Study, Medical School of Nanchang University, Nanchang 330006, China
*These authors have contributed equally to this work
Jingao Li, email: firstname.lastname@example.org
Keywords: base excision repair (BER) genes, single nucleotide polymorphism (SNP), nasopharyngeal carcinoma (NPC), acute radiation toxicity, short-term efficacy
Received: April 07, 2017 Accepted: July 19, 2017 Published: August 10, 2017
Purpose: To explore whether polymorphisms in base excision repair (BER) pathway genes are predictors of (chemo)radiotherapy outcome in patients with nasopharyngeal carcinoma (NPC).
Methods: We genotyped five potentially functional single nucleotide polymorphisms (SNPs) of three genes in the BER pathway in 174 NPC patients who were treated with (chemo)radiotherapy. Sequenom MassArray was used for SNPs analysis. The efficacy at the end of radiotherapy and at 3 months after radiotherapy was evaluated by Response Evaluation Criteria in Solid Tumors (RECIST). Acute radiation toxicity was scored using Radiation Therapy Oncology Group and the European Organization for Research and Treatment of Cancer (RTOG/EORTC) acute radiation morbidity scoring criteria. Logistic regression was employed to assess the multivariate analyses.
Results: We found that the wide genotype GG of X-ray repair cross-complementing 1 (XRCC1) rs25489 (GG vs GA: OR=3.833, 95%CI=1.512-9.714, P=0.005; GG vs GA+AA: OR=3.610, 95%CI=1.496-8.713, P=0.004) and the wide genotype CC of 8-oxoguanine DNA glycosylase (OGG1) rs1052133 (CC vs GG: OR=0.263, 95%CI=0.073-0.951, P=0.042; CC vs CG+GG: OR=0.454, 95%CI=0.195-1.053, P=0.066) were positively and negatively associated with primary tumor efficacy at the end of radiotherapy, respectively. By contrast, no association was found between BER gene polymorphisms and the treatment outcomes at 3 months post-treatment or the treatment-related acute toxicities.
Conclusions: The SNPs of the BER genes may act as biomarkers for the curative effect of (chemo)radiotherapy. Further study with long-time follow-up and large population is needed for accurate assessment.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.